Table 3 Characteristics of patients who... | American Society of Hematology

Table 3

Characteristics of patients who experienced grade 3/4 thromboembolic events during prophylaxis

Patient	Characteristics at multiple myeloma diagnosis						Characteristics at VTE onset
Patient	Type of prophylaxis	Age, y	Sex	ISS stage	KPS score	Risk factors	VTE	Onset after enrollment, mo	Treatment
1	ASA	57	Male	II	70	rHuEpo	PE	1.57	Rd
2	ASA	55	Female	III	70	rHuEpo	PE	0.63	Rd
3	LMWH	58	Female	III	80	None	DVT	1.93	Rd
4	ASA	57	Female	I	70	rHuEpo	PE	0.87	Rd
5	ASA	61	Female	III	90	None	DVT	1.03	Rd
6	LMWH	52	Male	I	100	None	DVT	2.33	Rd
7	LMWH	56	Male	I	100	None	DVT	9.8	MPR

Patient	Characteristics at multiple myeloma diagnosis						Characteristics at VTE onset
Patient	Type of prophylaxis	Age, y	Sex	ISS stage	KPS score	Risk factors	VTE	Onset after enrollment, mo	Treatment
1	ASA	57	Male	II	70	rHuEpo	PE	1.57	Rd
2	ASA	55	Female	III	70	rHuEpo	PE	0.63	Rd
3	LMWH	58	Female	III	80	None	DVT	1.93	Rd
4	ASA	57	Female	I	70	rHuEpo	PE	0.87	Rd
5	ASA	61	Female	III	90	None	DVT	1.03	Rd
6	LMWH	52	Male	I	100	None	DVT	2.33	Rd
7	LMWH	56	Male	I	100	None	DVT	9.8	MPR

VTE indicates venous thromboembolism; ISS, International Staging System; KPS, Karnofsky performance status; ASA, aspirin; rHuEpo, recombinant human erythropoietin; PE, pulmonary embolism; Rd, lenalidomide and low-dose dexamethasone; LMWH, low-molecular-weight heparin; DVT, deep vein thrombosis; and MPR, melphalan, prednisone plus lenalidomide.

View Large

This Feature Is Available To Subscribers Only